(SIEGEL, et al., 2023)

Oral mucositis is defined as

(Raber-Durlacher et al., 2010)

(MICHINOBU et al., 2021)

therapy are to improve survival while minimizing

toxicities and preserving quality of life. Combining

modalities of therapy enhances these efforts.

(LCOSER, RODGERS 2003)

By the end of the

second week, the integrity of the mucosa is breached and ulceration

Development of mucositis depends on the type of cancer drug administered, the type of therapy (radiation, chemotherapy, or combined chemo-radiotherapy), dosage, and delivery schedule. Studies have shown that the risk for oral mucositis increases as the intensity of therapy increases [13]. Chemotherapeutic agents with the highest risk include 5-FU, cisplatin, cyclophosphamide, and methotrexate. Oral mucositis risk depends also on the chemotherapy cycle. The risk for oral mucositis increases with increasing

cycles of therapy;